select semaglutide trial and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the semaglutide studies SELECT Trial Cardiovascular

The heart Lower inflammation tied to the drugs protects the blood vessels

Tirzepatide's 5-day half-life means: After 5 days (1 half-life): 50% remains After 10 days (2 half-lives): 25% remains After 15 days (3 half-lives): 12.5% remains On your normal 7-day schedule, when you inject the next dose, approximately 38% of the previous dose is still circulating (calculated as 0.5^(7/5) = 0.38)

For those using BPC-157 to address gastrointestinal issues, this is often when digestive symptoms begin to stabilize more consistently

Clinical trials evaluating semaglutide for both diabetes management (SUSTAIN trials) and weight loss (STEP trials) did not identify bruising as a frequent adverse event compared to placebo groups

Deraison, C., & Vergnolle, N